Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Terlipressin continuous infusion · 1 trial · 2 indications
Rate of treatment emergent adverse events assessed by physical examination and laboratory safety
Serial sampling for determination of Terlipressin concentration and metabolite 8-lysine vasopressin in plasma at steady state (Css)
| Arm | Type | Description |
|---|---|---|
| Terlipressin acetate continuous infusion | EXPERIMENTAL | Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days |
| Name | Type | Description |
|---|---|---|
| Terlipressin acetate continuous infusion | DRUG | Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days |
Inclusion Criteria: * Patients with cirrhosis and refractory ascites who required 3 or more large volume (4 liters and more) paracenteses in the previous 60 days Exclusion Criteria: * Ascites with causes other than cirrhosis such as nephrogenic ascites or malignant ascites due to peritoneal carci...
Terlipressin continuous infusion is an investigational small molecule being studied for the treatment of cirrhosis, specifically for patients with cirrhosis and refractory ascites. It is administered as a continuous infusion and is currently in Phase 2 clinical development.
Terlipressin continuous infusion is being developed by BioVie Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol BIVI. The company is conducting clinical research to evaluate this treatment for patients with cirrhosis and refractory ascites.
Terlipressin continuous infusion is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being evaluated in clinical trials for safety and efficacy in patients with cirrhosis and refractory ascites.
Terlipressin continuous infusion has been studied in one completed Phase 2 clinical trial with the identifier NCT03107091. This trial, titled 'Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites,' enrolled 6 participants in the United States and was not randomized or blinded.
Terlipressin continuous infusion refers to the method of administration of the drug terlipressin, which is given as a continuous infusion rather than as bolus doses. The clinical trial NCT03107091 specifically evaluated this continuous infusion approach in patients with cirrhosis and refractory ascites.